About Shanghai Rightongene Biotechnology Company

The company was founded in 2012 and focuses on providing clinically valuable diagnostic products and services for accurate tumor classification, MRD monitoring, and early tumor screening and testing for precision oncology medicine, so that more people can be protected from cancer damage. The company's main business is R&D, production, sales and scientific research and testing services of in vitro diagnostic products (including testing instruments and test reagents). Currently, the main products are leukemia-related fusion gene detection kit, leukemia-related 15 fusion gene detection kit, immunoglobulin gene rearrangement test kit, human EGFR gene mutation test kit, human K-ras and Braf gene mutation test kit, UGT1A1 genotype test kit, human rubella virus nucleic acid detection kit, small ureaplasma nucleic acid detection kit, herpes simplex virus type 1+2 nucleic acid test kit, herpes simplex virus type 1+2 nucleic acid test kit, hepatitis B virus pre-C1896 gene mutation test kit Test kit, fully automatic sample processing system, fully automatic Biochip readers, fully automatic nucleic acid extraction and purification devices, cell sorters, etc. Corporate honors: 2017 Future Healthcare Top 100, Fengxian District Science and Technology Giant Enterprise, Top 100 Emerging Chinese Startup Companies, “Shanghai Specialized and New Technology Enterprise”, “Fengxian District Science and Technology Little Giant Enterprise”, etc.